These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

757 related articles for article (PubMed ID: 26565674)

  • 1. Broadly Neutralizing Antibodies Against HIV: New Insights to Inform Vaccine Design.
    Sadanand S; Suscovich TJ; Alter G
    Annu Rev Med; 2016; 67():185-200. PubMed ID: 26565674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. On the benefits of sin: can greater understanding of the 1F7-idiotypic repertoire freeze enhance HIV vaccine development?
    Parsons MS; Muller S; Kohler H; Grant MD; Bernard NF
    Hum Vaccin Immunother; 2013 Jul; 9(7):1532-8. PubMed ID: 23571168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Catch Me If You Can--The Race Between HIV and Neutralizing Antibodies.
    Geiß Y; Dietrich U
    AIDS Rev; 2015; 17(2):107-13. PubMed ID: 26035168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Report of the Cent Gardes HIV Vaccine Conference: The B-cell Response to HIV. Part 1: Broadly Neutralizing Antibodies Fondation Mérieux Conference Center, Veyrier du Lac, France, 5-7 November 2012.
    Girard MP; Picot V; Longuet C; Nabel GJ
    Vaccine; 2013 Jun; 31(29):2979-83. PubMed ID: 23499518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Broadly neutralizing antibodies: What is needed to move from a rare event in HIV-1 infection to vaccine efficacy?
    Subbaraman H; Schanz M; Trkola A
    Retrovirology; 2018 Jul; 15(1):52. PubMed ID: 30055627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Broadly neutralizing antibodies against HIV-1: templates for a vaccine.
    van Gils MJ; Sanders RW
    Virology; 2013 Jan; 435(1):46-56. PubMed ID: 23217615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of an anti-HIV vaccine eliciting broadly neutralizing antibodies.
    Ahmed Y; Tian M; Gao Y
    AIDS Res Ther; 2017 Sep; 14(1):50. PubMed ID: 28893278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poly- and autoreactivity of HIV-1 bNAbs: implications for vaccine design.
    Finney J; Kelsoe G
    Retrovirology; 2018 Jul; 15(1):53. PubMed ID: 30055635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress in HIV vaccine development.
    Hsu DC; O'Connell RJ
    Hum Vaccin Immunother; 2017 May; 13(5):1018-1030. PubMed ID: 28281871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1.
    Kwong PD; Mascola JR; Nabel GJ
    Cold Spring Harb Perspect Med; 2011 Sep; 1(1):a007278. PubMed ID: 22229123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 Vaccines Based on Antibody Identification, B Cell Ontogeny, and Epitope Structure.
    Kwong PD; Mascola JR
    Immunity; 2018 May; 48(5):855-871. PubMed ID: 29768174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GP120: target for neutralizing HIV-1 antibodies.
    Pantophlet R; Burton DR
    Annu Rev Immunol; 2006; 24():739-69. PubMed ID: 16551265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenges for structure-based HIV vaccine design.
    Schief WR; Ban YE; Stamatatos L
    Curr Opin HIV AIDS; 2009 Sep; 4(5):431-40. PubMed ID: 20048708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of broadly neutralizing antibodies in HIV-1 infected elite neutralizers.
    Landais E; Moore PL
    Retrovirology; 2018 Sep; 15(1):61. PubMed ID: 30185183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design.
    Burton DR; Hangartner L
    Annu Rev Immunol; 2016 May; 34():635-59. PubMed ID: 27168247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Neutralizing Antibody Response to the HIV-1 Env Protein.
    Moore PL
    Curr HIV Res; 2018; 16(1):21-28. PubMed ID: 29173180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV Vaccines: One Step Closer.
    Low MSY; Tarlinton D
    Trends Mol Med; 2017 Jan; 23(1):1-3. PubMed ID: 27889424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody B cell responses in HIV-1 infection.
    Mouquet H
    Trends Immunol; 2014 Nov; 35(11):549-61. PubMed ID: 25240985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunological tolerance as a barrier to protective HIV humoral immunity.
    Schroeder KM; Agazio A; Torres RM
    Curr Opin Immunol; 2017 Aug; 47():26-34. PubMed ID: 28728075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers.
    Gupta S; Clark ES; Termini JM; Boucher J; Kanagavelu S; LeBranche CC; Abraham S; Montefiori DC; Khan WN; Stone GW
    J Virol; 2015 Apr; 89(8):4158-69. PubMed ID: 25631080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.